<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03942380</url>
  </required_header>
  <id_info>
    <org_study_id>1301261</org_study_id>
    <nct_id>NCT03942380</nct_id>
  </id_info>
  <brief_title>Cell-free Tumor DNA in Head and Neck Cancer Patients</brief_title>
  <official_title>Cell-free Tumor DNAand HPV-DNA in Blood Samples From Newly Diagnosed Patients With Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christian von Buchwald</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Copenhagen University Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Otorhinolaryngology, Head and Neck Surgery and Audiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates if head and neck squamous cell carcinoma can be tracked with&#xD;
      cell-free tumor DNA, RNA or HPV-DNA, in blood samples from patients referred with suspicion&#xD;
      of cancer, and if it can be used in detecting recurrence in patients already diagnosed and&#xD;
      treated for head and neck squamous cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">February 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of head and neck cancer detected with a blood sample</measure>
    <time_frame>0 months</time_frame>
    <description>The primary outcome is to measure the percentage of head and neck squamous cell carcinomas that can be detected using a liquid biopsy (blood sample)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of head and neck cancer recurrence detected with a blood sample</measure>
    <time_frame>36 months</time_frame>
    <description>The primary outcome is to measure the percentage of recurrence in head and neck cancer patients through serial monitoring with liquid biopsies (blood sample)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Oropharynx Cancer</condition>
  <condition>Oropharynx Neoplasm</condition>
  <condition>Oropharynx Carcinoma</condition>
  <condition>Oral Cavity Cancer</condition>
  <condition>Oral Cancer</condition>
  <condition>Oral Neoplasm</condition>
  <condition>Larynx Cancer</condition>
  <condition>Larynx Carcinoma</condition>
  <condition>Larynx Neoplasm</condition>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Nasopharyngeal Cancer</condition>
  <condition>Nasopharynx Neoplasm</condition>
  <condition>Hypopharynx Cancer</condition>
  <condition>Hypopharynx Neoplasm</condition>
  <condition>Hypopharynx Carcinoma</condition>
  <condition>Sinonasal Carcinoma</condition>
  <condition>Thyroid Carcinoma</condition>
  <condition>Thyroid Cancer</condition>
  <condition>Thyroid Neoplasms</condition>
  <condition>Salivary Gland Cancer</condition>
  <condition>Salivary Gland Neoplasms</condition>
  <condition>Salivary Gland Carcinoma</condition>
  <condition>Sinonasal Cancer</condition>
  <condition>Sinonasal Neoplasm</condition>
  <arm_group>
    <arm_group_label>Cell-free tumor DNA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The aim is to differentiate between patients with head and neck cancer from those without based on a blood sample.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Identifying recurrence</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The aim is to identify recurrence through serial monitoring patients with blood samples.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Liquid biopsy</intervention_name>
    <description>The intervention is a liquid biopsy as a blood sample taken in a peripheral vein. The blood samples are analyzed for cell free DNA, RNA and HPV-DNA</description>
    <arm_group_label>Cell-free tumor DNA</arm_group_label>
    <arm_group_label>Identifying recurrence</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 years old or older&#xD;
&#xD;
          -  Suspicion of head and neck cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with cancer within the last 3 years ( apart from basal cell carcinoma)&#xD;
&#xD;
          -  Diagnosed with an inflammatory or haematological disease after the age of 18&#xD;
&#xD;
          -  Received chemotherapy or immunosuppressive treatment within the last 3 years&#xD;
&#xD;
          -  Underwent a FNA ( fine-needle aspiration biopsy) or a biopsy from the head and neck&#xD;
             region within 1 week.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Von Buchwald, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Otorhinolaryngology, Head and Neck Surgery and Audiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Grønhøj, MD, Ph.D</last_name>
    <phone>004526276374</phone>
    <email>Christian.groenhoej@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Copenhagen, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>Region Hovedstaden</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Christian von Buchwald</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
    <mesh_term>Laryngeal Diseases</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

